Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · IEX Real-Time Price · USD
145.69
+1.55 (1.08%)
At close: Jul 19, 2024, 4:00 PM
158.45
+12.76 (8.76%)
Pre-market: Jul 22, 2024, 4:08 AM EDT
Neurocrine Biosciences Employees
Neurocrine Biosciences had 1,400 employees as of December 31, 2023. The number of employees increased by 200 or 16.67% compared to the previous year.
Employees
1,400
Change (1Y)
200
Growth (1Y)
16.67%
Revenue / Employee
$1,415,714
Profits / Employee
$264,071
Market Cap
14.66B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1,400 | 200 | 16.67% |
Dec 31, 2022 | 1,200 | 300 | 33.33% |
Dec 31, 2021 | 900 | 55 | 6.51% |
Dec 31, 2020 | 845 | 145 | 20.71% |
Dec 31, 2019 | 700 | 115 | 19.66% |
Dec 31, 2018 | 585 | 185 | 46.25% |
Dec 31, 2017 | 400 | 204 | 104.08% |
Dec 31, 2016 | 196 | 76 | 63.33% |
Dec 31, 2015 | 120 | 26 | 27.66% |
Dec 31, 2014 | 94 | 13 | 16.05% |
Dec 31, 2013 | 81 | 3 | 3.85% |
Dec 31, 2012 | 78 | 7 | 9.86% |
Dec 31, 2011 | 71 | 5 | 7.58% |
Dec 31, 2010 | 66 | 1 | 1.54% |
Dec 31, 2009 | 65 | -60 | -48.00% |
Dec 31, 2008 | 125 | -10 | -7.41% |
Dec 31, 2007 | 135 | -132 | -49.44% |
Dec 31, 2006 | 267 | -321 | -54.59% |
Dec 31, 2005 | 588 | 203 | 52.73% |
Dec 31, 2004 | 385 | 40 | 11.59% |
Dec 31, 2003 | 345 | 69 | 25.00% |
Dec 31, 2002 | 276 | 54 | 24.32% |
Dec 31, 2001 | 222 | 34 | 18.09% |
Dec 31, 2000 | 188 | 37 | 24.50% |
Dec 31, 1999 | 151 | 2 | 1.34% |
Dec 31, 1998 | 149 | 41 | 37.96% |
Dec 31, 1997 | 108 | 5 | 4.85% |
Dec 31, 1996 | 103 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Quest Diagnostics | 48,000 |
Viatris | 38,000 |
Molina Healthcare | 18,000 |
Revvity | 11,500 |
BeiGene | 10,600 |
BioMarin Pharmaceutical | 3,401 |
Insulet | 3,000 |
Incyte | 2,524 |
NBIX News
- 2 days ago - Neurocrine's Growing Sales, Profits Attracting Big Money - FXEmpire
- 3 days ago - Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing - PRNewsWire
- 10 days ago - Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results - PRNewsWire
- 21 days ago - Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH - PRNewsWire
- 6 weeks ago - Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024 - PRNewsWire
- 7 weeks ago - Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine - PRNewsWire
- 7 weeks ago - Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine - PRNewsWire
- 7 weeks ago - Neurocrine Biosciences to Participate at Investor Conferences in June - PRNewsWire